Insiders · XFOR

XFOR insider transactions

X4 Pharmaceuticals Inc. (XFOR) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for XFOR

• 21d
  Chief Financial Officer Kirske David sold $72,820 worth of shares (16,961 units at $4.29), decreasing direct ownership by 9% to 176,293 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 147d
  SEC Form 4 filed by Director Bridger Gary

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 149d
  SEC Form 4 filed by Director De Craecker Francoise

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 149d
  SEC Form 4 filed by Director Wyzga Michael S

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 149d
  SEC Form 4 filed by Director Stewart Murray

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 215d
  SEC Form 4 filed by President Volpone John

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 215d
  SEC Form 4 filed by Executive Chairman Craig Adam R

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 215d
  SEC Form 4 filed by Chief Financial Officer Kirske David

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 218d
  Executive Chairman Craig Adam R bought $249,997 worth of shares (86,206 units at $2.90), increasing direct ownership by 30% to 376,087 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 292d
  President Volpone John was granted 289,881 shares (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 292d
  SEC Form 3 filed by new insider Craig Adam R

  3 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 292d
  SEC Form 3 filed by new insider Kirske David

  3 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 292d
  Executive Chairman Craig Adam R was granted 289,881 shares (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 292d
  Chief Financial Officer Kirske David was granted 193,254 shares (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 292d
  SEC Form 3 filed by new insider Volpone John

  3 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 335d
  Chief Legal Officer Thoren Natasha Fay was granted 3,333 shares, increasing direct ownership by 54% to 9,462 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 358d
  Director Stewart Murray was granted 1,500 shares, increasing direct ownership by 23% to 7,883 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 358d
  Director De Craecker Francoise was granted 1,500 shares, increasing direct ownership by 47% to 4,722 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 358d
  Director Bridger Gary was granted 1,500 shares, increasing direct ownership by 47% to 4,722 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 358d
  Director Woods Keith was granted 1,500 shares, increasing direct ownership by 33% to 6,000 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 358d
  Director Mcgirr David W J was granted 1,500 shares, increasing direct ownership by 47% to 4,722 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 358d
  Director Wyzga Michael S was granted 1,500 shares, increasing direct ownership by 37% to 5,555 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 365d
  New insider Thoren Natasha Fay claimed ownership of 6,984 shares (SEC Form 3)

  3 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 365d
  Amendment: Chief Commercial Officer Baldry Mark was granted 1,032 shares, increasing direct ownership by 4% to 25,337 units (SEC Form 4)

  4/A - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 379d
  Chief Commercial Officer Baldry Mark bought $2,561 worth of shares (1,032 units at $2.48), increasing direct ownership by 4% to 25,337 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 474d
  Chief Medical Officer Arbet-Engels Christophe was granted 850,000 shares, increasing direct ownership by 5,983% to 864,207 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 474d
  Chief Financial Officer Mostafa Adam S. was granted 850,000 shares (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 474d
  President and CEO Ragan Paula was granted 2,250,000 shares, increasing direct ownership by 207% to 3,337,386 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 474d
  Chief Operating Officer Dibiase Mary was granted 650,000 shares, increasing direct ownership by 132% to 1,140,980 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 474d
  Chief Commercial Officer Baldry Mark bought $19,252 worth of shares (35,050 units at $0.55) and was granted 600,000 shares, increasing direct ownership by 675% to 729,173 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 491d
  President and CEO Ragan Paula was granted 169,940 shares and sold $34,719 worth of shares (76,473 units at $0.45), increasing direct ownership by 9% to 1,087,386 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 491d
  Chief Financial Officer Mostafa Adam S. was granted 74,773 shares and sold $33,947 worth of shares (74,773 units at $0.45) (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 491d
  Chief Commercial Officer Baldry Mark was granted 74,773 shares and sold $13,241 worth of shares (29,159 units at $0.45), increasing direct ownership by 94% to 94,123 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 491d
  Chief Operating Officer Dibiase Mary was granted 61,178 shares and sold $10,094 worth of shares (22,258 units at $0.45), increasing direct ownership by 9% to 490,980 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 491d
  Chief Medical Officer Arbet-Engels Christophe was granted 25,831 shares and sold $5,284 worth of shares (11,624 units at $0.45) (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 561d
  President and CEO Ragan Paula sold $12,583 worth of shares (31,897 units at $0.39), decreasing direct ownership by 3% to 993,919 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 595d
  President and CEO Ragan Paula sold $17,926 worth of shares (31,897 units at $0.56), decreasing direct ownership by 3% to 1,025,816 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 603d
  Chief Financial Officer Mostafa Adam S. was granted 230,645 shares and sold $126,901 worth of shares (230,645 units at $0.55) (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 603d
  President and CEO Ragan Paula was granted 532,081 shares and sold $131,522 worth of shares (239,436 units at $0.55), increasing direct ownership by 38% to 1,057,713 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 603d
  Chief Operating Officer Dibiase Mary sold $38,329 worth of shares (67,695 units at $0.57) and was granted 230,645 shares, increasing direct ownership by 56% to 452,060 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 603d
  Chief Commercial Officer Baldry Mark was granted 34,946 shares and sold $6,506 worth of shares (11,127 units at $0.58), increasing direct ownership by 96% to 48,509 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 603d
  Chief Scientific Officer Taveras Arthur was granted 230,645 shares and sold $43,306 worth of shares (76,920 units at $0.56), increasing direct ownership by 66% to 388,026 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 630d
  Chief Operating Officer Dibiase Mary sold $1,738 worth of shares (2,642 units at $0.66), decreasing direct ownership by 0.91% to 289,110 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director De Craecker Francoise was granted 45,000 shares, increasing direct ownership by 87% to 96,667 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Aliski William was granted 45,000 shares, increasing direct ownership by 87% to 96,667 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Mcgirr David W J was granted 45,000 shares, increasing direct ownership by 87% to 96,667 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Stewart Murray was granted 45,000 shares, increasing direct ownership by 31% to 191,504 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Bridger Gary was granted 45,000 shares, increasing direct ownership by 87% to 96,667 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Woods Keith was granted 45,000 shares, increasing direct ownership by 50% to 135,000 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Lawton Alison Frances was granted 45,000 shares, increasing direct ownership by 87% to 96,667 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 722d
  Director Wyzga Michael S was granted 45,000 shares, increasing direct ownership by 59% to 121,667 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 814d
  Taveras Arthur sold $12,552 worth of shares (14,235 units at $0.88), decreasing direct ownership by 6% to 234,301 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 814d
  Ragan Paula sold $43,856 worth of shares (49,678 units at $0.88), decreasing direct ownership by 6% to 765,068 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 814d
  Mostafa Adam S. sold $46,347 worth of shares (52,500 units at $0.88), closing all direct ownership in the company (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 814d
  Dibiase Mary sold $13,591 worth of shares (15,409 units at $0.88), decreasing direct ownership by 5% to 291,752 units (SEC Form 4)

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 825d
  SEC Form 4 filed by Arbet-Engels Christophe (Amendment)

  4/A - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 838d
  SEC Form 4 filed by Arbet-Engels Christophe

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 838d
  SEC Form 4 filed by Mostafa Adam S.

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 838d
  SEC Form 4 filed by Dibiase Mary

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
• 838d
  SEC Form 4 filed by Ragan Paula

  4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)